|
Indian Pediatr 2019;56: 423- 425 |
|
Achromobacter
xylosoxidans Sepsis Unveiling X-linked Agammaglobulinemia
Masquerading as Systemic-onset Juvenile Idiopathic Arthritis
|
Mahesh Janarthanan 1,
Sameera Gollapalli2
and Shuba Sankaranarayanan2
From 1Division of Pediatric
Rheumatology, and 2Department of Pediatrics, Sri
Ramachandra Institute of Higher Education and Research, Chennai, India.
Correspondence to: Dr Mahesh Janarthanan, Division of
Pediatric Rheumatology, Department of
Pediatrics, Sri Ramachandra Institute of Higher Education and Research,
Chennai, India.
Email:
[email protected]
Received: July 28, 2018;
Initial review: January 03, 2019:
Accepted: March 16, 2019.
|
Background: X-linked agammaglobulinemia, a primary immunodeficiency,
can present with musculoskeletal manifestations. Case
characteristics: A 4-year-old boy, diagnosed as systemic juvenile
idiopathic arthritis at the age of 3 years and treated with biological
agents, presented with fever, dyspnea and chest pain. Blood culture and
pericardial fluid culture revealed Achromobacter xylosoxidans.
Outcome: Investigation revealed normal serum ferritin but low levels
of serum immunoglobulins. Further immunological work-up revealed
diagnosis of X-linked agammaglobulinemia. Child improved on antibiotic
therapy; treatment with steroids and biological was discontinued.
Message: Underlying immunodeficiency disease must be looked for in
children suspected to have juvenile arthritis, more so if they develop
unusual serious infection in response to immunomodulatory therapy.
Key messages: Pericarditis, Macrophage activation syndrome,
Primary immune deficiency.
|
X -Linked agammaglobulinemia (XLA) or Bruton’s
agammaglobulinemia is characterized by a severe congenital defect in the
development of B lymphocytes. This results in absence of circulating B
cells, severe pan-hypogammaglobulinemia and absent lymphoid tissue such
as tonsils or lymph nodes. Children with XLA tend to present with
recurrent infections of the respiratory tract with extracellular
pyogenic organisms like Streptococcus pneumoniae and
Hemophilus influenzae, diarrhea, and skin infections. They can also
have severe infections like septicemia or meningitis [1] or uncommonly
musculoskeletal manifestations [2,3]. Systemic juvenile idiopathic
arthritis (SJIA), an autoinflammatory disease characterized by the
presence of fever, rashes, arthritis, serositis, lymphadenopathy and
hepatosplenomegaly, can present similarly [4].
Case Report
A 4-year-old boy, who was born by assisted
conception, presented with a history of shortness of breath, chest pain
and low grade fever for 6 days. He had nocturnal chest pain and was
unable to lie down supine. About 2 weeks prior to this presentation, he
had bilateral ear infection for which he received treatment with oral
amoxicillin/clavulanic acid and azithromycin. There was no significant
medical history in the family and the child had a healthy 10-year-old
female sibling.
The boy had been well until three years of age,
except for occasional episodes of ear infections. He had also been
immunized as per schedule, and had received live vaccines including oral
polio and Measles Mumps Rubella (MMR) vaccines without any adverse
events. At three years of age, he presented with fever, and arthritis
involving multiple joints for more than a month duration, and was
diagnosed as having SJIA at a peripheral hospital. Investigations
revealed total blood count 29×10 9/L,
differential blood count with neutrophils 84% and lymphocytes 9%,
platelet count 693×109/L and
CRP 82 mg/dL. It is likely that he received empirical antibiotics during
this episode; although, no discharge summary was available. He had been
treated with oral methotrexate 15 mg/m2
and folic acid 5 mg once a week. After being on this
treatment for a year, as there was no improvement of arthritis, he was
treated with Tocilizumab (anti-interleukin 6 receptor antibody)
infusions every 2 weeks. He developed bilateral ear infection at the
time of third dose of the biologic agent.
When he presented to us, he had tachypnea
(respiratory rate of 36/min) and tachycardia (heart rate of 120/min),
but was maintaining 100% oxygen saturation in room air. Liver was
palpable 2 cm below right costal margin and the spleen was palpable 6 cm
below left costal margin. He also had bilateral knee effusion. There was
no lymphadenopathy. Bedside echocardiogram revealed moderate to large
pericardial effusion. Baseline blood tests showed Hemoglobin 9.3 g/dL,
total leukocyte count 4.5×10 9/L,
platelet count 85×109/L, ESR
42 mm/hr and CRP 2.4 mg/dL. Considering initial diagnosis of systemic
juvenile arthritis and investigations showing pericardial effusion, low
white cell and platelet count, macrophage activation syndrome was
suspected. He was started on high dose methylprednisolone and empirical
broad spectrum antibiotics (piperacillin/tazobactum and cloxacillin).
However, laboratory investigations revealed serum
ferritin 105.2 ng/mL, fasting triglycerides 105 mg/dL, serum fibrinogen
308 mg/dL (normal 250-530 mg/dL), d-dimers 190 mg/dL (normal 170-405 mg/dL);
all within normal range. C3 was low (61 mg/dL) and C4 (17.9 mg/dL)
slightly towards lower range of normal (17.4-52.2 mg/dL). Anti-nuclear
antibody (ANA) and double stranded DNA were negative. Mantoux test was
negative and gastric aspirates were negative for acid-fast bacilli.
Serology for CMV, EBV, HIV and Parvovirus were negative. A bone marrow
aspirate revealed normocellular reactive marrow and the bone biopsy
showed hypocellular reactive marrow with trilineage hematopoesis. The
clinical and laboratory parameters did not fit with SJIA, or its
complication macrophage activation syndrome [5].
At this stage, pericardiocentesis was done in view of
respiratory distress and increasing effusion. Pericardial fluid analysis
revealed a hemorrhagic exudate with protein of 3.6 g/dL, glucose 35 mg/dL,
white cell count 7300 cells/mm 3;
polymorphs 75%, lymphocytes 25%, red blood cells 86000 cells/mm3.
Gram’s and acid-fast staining of the fluid were negative. GeneXpert for
Mycobacterium tuberculosis was negative. Cell cytology was
negative for malignant cells and showed predominantly neutrophils and
few lymphocytes.
Blood culture at admission and pericardial fluid
cultures done on day 3, 8 and 11 revealed Achromobacter xylosoxidans
sensitive to amoxicillin/clavulanic acid, cefoperazone with sulbactum,
cefepime, co-trimoxazole, piperacillin/tazobactum and resistant to
amikacin, ceftriaxone, cefuroxime, ciprofloxacin and gentamicin.
Piperacillin/tazobactum was continued and oral co-trimoxazole was added.
As a primary immunodeficiency was considered at this
stage, serum immunoglobulins were tested, and this revealed
panhypogammaglobulinemia with IgG <137 (normal 504-1411 mg/dL), IgA <26
(27-195 mg/dL), IgM <17.8 (normal 24-210 mg/dL). Flowcytometry analysis
showed complete absence of CD19 B lymphocytes, CD3 T lymphocytes 1479
(normal 1600-2700 cells/mm 3),
CD3/CD4 Th lymphocytes 736 (normal 700-2200 cells/mm3),
CD3/CD4 Tc lymphocytes 674 (normal 490-1200 cells/mm3),
CD3 /CD16 NK cells 164 (normal 130-720 cells/mm3).
Gene sequencing revealed a hemizygous mutation (p.Asn72fs) in BTK
gene. The mother of the patient was a heterozygous carrier for this
mutation.
The patient improved with intravenous immunoglobulin
(IVIG) therapy and antibiotics were prescribed for six weeks. Steroids
were weaned rapidly. Splenomegaly regressed and arthritis resolved with
treatment. The patient continues on regular IVIG replacement therapy and
is well on follow-up.
Discussion
Achromobacter xylosoxidans also known as
Alcaligenes xylosoxidans is a gram negative bacilli found in water
and soil. It is an uncommon cause for infection but may cause bacteremia,
pneumonia, osteomyelitis, abscess, meningitis or ear infections in
immunocompetent and immunocompromised patients. It has also been
isolated from the gut and ear canal. Infection with this organism can
result in significant mortality in children [6]. In our child, the
likely source of Achromobacter xylosoxidans could have been from
his recent ear infection. In addition to the underlying immune-deficient
state, biologic therapy might have facilitated the spread of the
infection into the blood stream and pericardial fluid.
The association between immune deficiency and
autoimmune inflammatory manifestations is known. Joint manifestations in
primary immune deficiency may occur due to inflammation or infection
[3,4]. An Indian series of 28 patients reported arthritic manifestations
in 42% of patients, and this was attributed to low IgG levels in these
patients [7]. Defective B-cell tolerance has been postulated to
contribute to infection susceptibility in inflammatory conditions [3].
There have been previous published reports of XLA presenting with
features of juvenile arthritis and of Achromobacter xylosoxidans
infection in primary immunodeficiencies [8,9]. The disease course in
this patient was complicated due to misdiagnosis, the immune-modulation
therapy he was subjected to, and the unusual infection he developed as a
result.
Children on therapy with biological agents are at an
increased risk of infections. Published literature on this subject
reveals higher incidence of pneumonia, gastroenteritis, chickenpox, and
ear infections but opportunistic infections were less likely [10]. The
patient presented to us with clinical features of fever, arthritis,
hepatosplenomegaly and pericardial effusion. These features fit very
well with a flare of SJIA, and this led to the patient being started on
intravenous pulse therapy of steroids in addition to empirical
antibiotics. The low white cell count, thrombocytopenia and the low CRP
in this patient inspite of severe infection may be attributed to recent
therapy with biological agents. It was the isolation of Achromobacter
xylosoxidans in the blood culture and pericardial fluid that
prompted us to look for an alternative diagnosis.
In young children presenting with arthritis,
particularly in those with history of recurrent ear infections or other
serious infections, a primary immune deficiency should be considered.
The case highlights the importance of complete evaluation of children
with joint disease before making a diagnosis of juvenile idiopathic
arthritis and the serious risks associated with immunosuppression in
patients with immune deficiencies.
Acknowledgement: Dr Amit Rawat, Pediatric
Allergy Immunology Unit, PGIMER, Chandigarh for carrying out genetic
studies in the family.
Contributors: MJ, SS: contributed to diagnostic
work-up of patient and supervised patient management; SG: drafted the
manuscript, which was revised by MJ and SS. All authors approved the
final version of manuscript.
Funding: None; Competing interest: None
stated.
References
1. Winkelstein JA, Marino MC, Lederman HM, Jones SM,
Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: Report
on a United States registry of 201 patients. Medicine. 2006; 85:193-202.
2. Hernandez-Trujillo VP, Scalchunes C,
Cunningham-Rundles C, Ochs HD, Bonilla FA, Paris K, et al.
Autoimmunity and Inflammation in X-linked Agammaglobulinemia. J Clin
Immunol. 2014;34:627-32.
3. Gharib A, Gupta S. Skeletal and joint
manifestations of primary immunodeficiency diseases. SOJ Immunol.
2016;4:1-13.
4. Hofer M, Southwood TR. Classification of childhood
arthritis. Best Prac Res Clinic Rheumatol. 2002;16:379-96.
5. Ravelli A, Minoia F, Davý S, Horne AC, Bovis F,
Pistorio A, et al. 2016 classification criteria for macrophage
activation syndrome complicating systemic juvenile idiopathic arthritis.
Arthritis Rheumatol. 2016;68:566-76.
6. Igra-Siegman A, Chmel H, Cobbs C. Clinical and
laboratory characteristics of achromobacter xylosoxidans infection. J
Clin Microbiol.1980;11:141-5.
7. Singh S, Rawat A, Suri D, Gupta A, Garg R, Saikia
B, et al. X-linked agammaglobulinemia: Twenty years of
single-center experience from North West India. Ann Allergy Asthma
Immunol. 2016;4:405-11.
8. Sheehan WJ, Delmonte OM, Miller DT, Roberts AE,
Bonilla FA, Morra M, et al. Novel presentation of Omenn syndrome
in association with aniridia. J Allergy Clin Immunol. 2010;4: 967-8.
9. Weitkamp J-H,Tang Y-W, Haas DW, Midha NK, Crowe
JE, Jr. Recurrent achromobacter xylosoxidans bacteremia
associated with persistent lymph node infection in a patient with
hyper–immunoglobulin M syndrome. Clin Infect Dis. 2000;31:1183-7.
10. Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and
tolerability of tocilizumab in patients with systemic juvenile
idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4:387-97.
|
|
|
|